-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

Benzinga·04/16/2025 11:06:19
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Buy and maintains $38 price target.